1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.A successful company that fits this billing is Medpace (NASDAQ: MEDP), a leading clinical contract research organization. Medpace offers a full suite of development services for small to medium-sized biotechs, helping them get from phase I to phase IV (and beyond) in the clinical trial process. Serving this niche, Medpace has been an 11-bagger since its initial public offering (IPO) in 2016 -- quintupling the S&P 500's total returns over the same time.Despite this promising run, however, funding in the cyclical biotech industry declined over the last year, causing Medpace's growth to slow and its share price to plummet 34%. Though this share price drop may seem alarming, I believe Medpace is positioned to rebound -- just as it has in the past -- and makes for a spectacular growth stock to buy after its recent sell-off.Continue reading
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.
A successful company that fits this billing is Medpace (NASDAQ: MEDP), a leading clinical contract research organization. Medpace offers a full suite of development services for small to medium-sized biotechs, helping them get from phase I to phase IV (and beyond) in the clinical trial process. Serving this niche, Medpace has been an 11-bagger since its initial public offering (IPO) in 2016 -- quintupling the S&P 500's total returns over the same time.
Despite this promising run, however, funding in the cyclical biotech industry declined over the last year, causing Medpace's growth to slow and its share price to plummet 34%. Though this share price drop may seem alarming, I believe Medpace is positioned to rebound -- just as it has in the past -- and makes for a spectacular growth stock to buy after its recent sell-off.
